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Background: NSAIDs are associated with risks of
gastrointestinal (GI) and cardiovascular (CV) toxic-
ities. It has been reported that the risks of GI and CV
events are dose related, resulting in guidance explicitly
emphasizing the use of NSAIDs at the lowest effective
dose for the shortest duration. To understand the
potential beneﬁts of using lower doses of diclofenac, a
more detailed understanding of the relationship of
diclofenac dose and the risks of GI and CV events is
required.
Objective: The objective of this study was to extend
previous research quantifying the NSAID dose–tox-
icity relationship by modeling dose as a continuous
measure, allowing for an assessment of the risks of
major GI and CV events for patients taking speciﬁc
diclofenac doses compared with NSAID nonusers.
Methods: We used studies identiﬁed in 2 recently
published systematic reviews of observational studies
that examined the risks of major GI and CV events
associated with the use of oral NSAIDs. We developed
meta-regression models, considering dose as a contin-
uous measure, to estimate the risks of major GI and
CV events for different daily doses of conventional
oral diclofenac relative to nonuse of NSAIDs.
Results: Seven of the 59 GI publications, contribu-
ting 11 dose-speciﬁc risk ratio observations, and 12 of
the 51 CV studies, contributing 21 dose-speciﬁc risk
ratio observations, were eligible for inclusion in the
meta-regression. The models indicated positive linear
relationships between diclofenac dose and the relative
risks of major GI and CV events for the range of doses
examined.
Conclusions: To our knowledge, this is the ﬁrst
study to quantify and aggregate the continuous
relationship between the risk of GI or CV events906and the dosage of an NSAID. With the recent avail-
ability of new low doses of diclofenac, the models may
be used to estimate the potential reduction in risk of
adverse events at these doses. (Clin Ther.
2014;36:906–917) & 2014 The Authors. Published
by Elsevier HS Journals, Inc.
Key Words: cardiovascular safety, diclofenac, dose-
related toxicity, gastrointestinal complications, meta-
analysis.INTRODUCTION
NSAIDs are a diverse group of medications used to
treat patients with acute and chronic pain as well as to
reduce inﬂammation.1 Although NSAIDs are com-
monly prescribed due to their proven efﬁcacy in treat-
ing pain, they often present safety and tolerability
issues, including serious concerns related to gastro-
intestinal (GI), cardiovascular (CV), and renal toxi-
city. Traditional, nonselective NSAIDs such as
diclofenac have been associated with GI events and
in particular upper GI bleeding/perforation (UGIB).2
Efforts have been taken to mediate NSAID toxicity,
including use of proton pump inhibitors for their
gastroprotective effects, development of cyclooxy-
genase-2 (COX-2) selective inhibitors, and develop-
ment of topical NSAIDs. Newer, COX-2–selective
NSAIDs were developed in part for the potential to
reduce the risk of GI events but have subsequently
demonstrated an increased risk of CV events. InVolume 36 Number 6
D.M. Odom et al.particular, rofecoxib, a COX-2–selective inhibitor,
was removed from the market in late 2004 when a
clinical study demonstrated that the drug was asso-
ciated with increased rates of CV events in patients
with colorectal polyps.3 Subsequently, efforts focused
on understanding whether the risks observed with
rofecoxib were also present for other COX-2–selective
inhibitors and for nonselective NSAIDs.
Large pharmacoepidemiologic studies4–6 corroborated
ﬁndings from NSAID clinical trials of toxicity risks.
Additional studies have examined the risk of low versus
high doses of NSAIDs and found increased safety risks
for patients receiving high doses of NSAIDs compared
with patients receiving low doses of these agents.7–11
Based on pooled evidence, regulatory agencies, including
the US Food and Drug Administration,12 the European
Medicines Agency,13 and Health Canada,14 have
explicitly recommended the use of NSAIDs at the
lowest effective dose for the shortest duration.
In the present study, we examined the dose–toxicity
relationship of conventional oral diclofenac to explore
the potential beneﬁts of the novel low-dose oral diclo-
fenac product* recently approved by the US Food and
Drug Administration as a treatment for acute pain.
Due to the low incidence of serious GI and CV
adverse events, conducting a randomized clinical trial
to determine the difference in serious GI and CV
adverse event rates between low-dose diclofenac and
conventional diclofenac would require a patient sample
size in the hundreds of thousands and a trial duration
of many years. In the absence of data from randomized
trials, the Methods Guide for Comparative Effective-
ness Studies by the Agency for Healthcare Research
and Quality15 recommends examining available
observational data by using appropriate statistical
techniques. Therefore, the data used to quantify the
relationship between diclofenac dosage and major GI
and CV adverse event risks were obtained from
publications of observational studies included in
recently published systematic literature reviews.
To our knowledge, no meta-analysis study has
attempted to quantify the continuous relationship
between the increased risk of major GI and CV events
and the increased dosage of diclofenac. This study
extends previous NSAID dose–toxicity research by
modeling dose as a continuous measure, allowing for*Trademark: Zorvolexs (Iroko Pharmaceuticals LLC, Philadel-
phia, Pennsylvania).
June 2014an assessment of the risks of GI and CV events for
patients taking speciﬁc conventional oral diclofenac
doses compared with NSAID nonusers.
METHODS
Data Sources
Given the wealth of information on the safety
proﬁle of NSAIDs, we were able to locate 2 recently
published systematic reviews of NSAID observational
studies that met our meta-regression objectives: a
systematic review of GI toxicity7 and a systematic
review of CV toxicity.8 The search strategy of
Castellsague et al7 was restricted to observational
studies published in English between January 1,
1980, and May 31, 2011, in the PubMed database.
The authors used MeSH terms and free-text terms for
individual NSAIDs and COX-2–selective inhibitors
and GI disease. The search strategy of McGettigan
and Henry8 was limited to electronic databases for
published articles (case-control, case-crossover, and
controlled cohort designs that reported on CV risks
associated with the use of the individual drugs in
population settings) between January 1, 1985, and
November 30, 2010, with no language restriction.
These 2 systematic reviews were used as the basis for
identifying potentially relevant diclofenac studies.
Additional Meta-Regression Inclusion
and Exclusion Criteria
We applied criteria to the published studies identi-
ﬁed in the 2 systematic reviews to assess the relation-
ship between GI and CV events and diclofenac dose
via meta-regression analyses. Speciﬁcally, from all the
studies included in the 2 published systematic liter-
ature reviews, we identiﬁed studies that included oral
diclofenac and evaluated GI or CV risks and then
reviewed each one to determine whether the study
reported dosing information. The criteria for selecting
studies for inclusion in the analysis were thoroughly
documented, including the development of a ﬂow
chart similar to the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses ﬂow chart.16
Drug Exposures and Outcomes
Exposure to diclofenac was based on “current use”
as deﬁned in each study. All studies deﬁned a dose in
milligrams, and none reported dose per weight (eg,
milligrams per kilogram). The majority of the studies
deﬁned exposure as any diclofenac use up to 30 days907
Clinical Therapeuticsbefore the event date (ie, the day on which the GI or
CV event occurred). Studies presented either a single
result for a total daily dose (a speciﬁc dosage or
dosage described by using summary statistics) or
results according to dosage category.
Where studies presented information according to
diclofenac dosage category (eg, the odds ratio of an
UGIB with diclofenac use of o100 mg daily), the
outcomes for GI and CV events were recorded by using
dose categories. We then derived a speciﬁc dosage based
on either the midpoint of the category or the most
commonly used dosage in the category; all dose deriva-
tions were conﬁrmed by 2 rheumatologists who are
experts in the use of NSAIDs. This step facilitated meta-
regression model development by associating the out-
come effect with a speciﬁc dose as a continuous measure.
For studies that presented a single overall GI or CV
risk ratio, dose was obtained from summary statistics
(eg, median). Finally, when a speciﬁc dosage was
presented, the outcome linked to that dosage was used.
Studies reported a mix of safety outcomes. A major-
ity of the GI studies reported on UGIB (ie, complicated
ulcer), with 2 studies reporting ﬁrst hospitalization for
an upper GI event.17,18 The most commonly reported
outcome in the CV studies was acute myocardial
infarction (AMI), with some studies reporting other
outcomes: CV disease, death, stroke, hospitalization
for a CV event, or a composite measure of multiple
outcomes. In their respective systematic reviews, McGet-
tigan and Henry8 allowed individual studies to
contribute 41 outcome whereas Castellsague et al7
did not. We followed the approach by Castellsague
et al, in which each study was allowed to contribute
only 1 outcome. We chose the outcome based on the
most commonly reported outcome across all the studies.
If a study presented 41 relevant outcome, a hierarchy
was imposed by clinical relevance, as follows:▪9GI event: UGIB was the most commonly reported
event. If a study did not report UGIB (1 study), we
used ﬁrst hospitalization for an upper GI event.▪ CV event: AMI was the most commonly reported
event. If a study did not report AMI, we used CV
disease, death, stroke, or hospitalization for a CV
event, in that order.
Statistical Analysis
A type of meta-analysis, meta-regression, was used
to quantify the dose–toxicity relationship of oral08diclofenac with serious upper GI and CV events.
Meta-analysis is a quantitative technique that integra-
tes and condenses information from independent
studies. Meta-regression is similar to simple regression
analyses in which an outcome variable is predicted
according to the values of a number of explanatory
(independent) variables.
In the 2 meta-regression models for this study, the
dependent variable was the risk ratio of the toxicity
event (ie, upper GI event, CV event). The meta-
regressions were based on a linear mixed-effects model
that accounted for within-study correlation for studies
that contributed 41 observation. The explanatory
variable was a continuous measurement of dosage.
The model was weighted by the inverse of the trial-
speciﬁc dependent variable precision (ie, variance). In
effect, this meant that studies with larger sample sizes
had more inﬂuence in the meta-regression model. SEs
of the effect estimate were derived by using the CI for
the outcome effect.
The meta-regression model was as follows:
For study i and dose j, the dependent variable (ie,
risk ratio) yij can be written as
yij ¼ 1 þ αxij þ γi þ εij,
where
yij is the dependent variable (ie, risk ratio) from
study i and dosage j▪ α is the ﬁxed effect associated with the change in
the dependent variable for 1-unit increase of dosage▪ xij is the dosage from study i and dosage j
▪ study-speciﬁc random intercept γi follows normal
distribution with mean zero and unknown common
variance s2▪ εij is the error term following a normal distribution
with mean zero and known variance sij
2 from study i
and dosage j▪ the error terms (εij) from each study are independ-
ent and the correlation between different doses (if
applicable) within a study is assumed to be 0.5▪ the error term (εij) and study-speciﬁc random
intercept (γi) are independent
We assumed that the odds ratio, incidence rate ratio,
and hazard ratio reported in studies all were equivalent
to the risk ratio on the basis of the low incidence
assumption.19 Incidence rates, where provided, were
converted to an incidence rate ratio based on the
incidence of GI events for the NSAID nonuser
population.20 This derivation was not necessary for theVolume 36 Number 6
D.M. Odom et al.CV end point because all of the studies provided an
outcome measure in terms of a ratio to NSAID nonusers.
We assumed that the risk ratio was 1 when the dose was
zero. This was accomplished by scaling the risk ratios
(subtracting 1 from the risk ratios) and setting the
intercept to zero. It was then necessary to add 1 to
any estimated results from the meta-regression to derive
the estimated risk ratios. From the model, we tested the
null hypothesis that α ¼ 0 versus α a 0 and if the test
was signiﬁcant (2-sided) at the 0.05 level, then we
concluded that there was a relationship between diclo-
fenac dose and GI/CV events.RESULTS
Literature Search and Characteristics
of Included Studies
GI Studies
Of the 59 GI publications selected by Castellsague
et al7 in their qualitative synthesis, 30 included diclofenac.
Of these, 7 studies presented daily dose data for oral
diclofenac and were appropriate for inclusion (Figure 1).
Of these 7 studies, 5 were case-control studies and 2 were
cohort studies. For the case-control studies, the number
of case subjects ranged from 175 to 2813, and the
number of control subjects ranged from 347 to 20,002.
Cases typically were deﬁned as adult patients with a ﬁrst-Studies eligible for meta-regression
(n = 7)
Individual studies used in qualitative synthesis
by Castellsague et al7 
(n = 59)
(28 used in meta analysis and
31 additional full text considered)
Studies with any dosing information
(n = 10)
Studies with diclofenac information
(n = 30)
Figure 1. Flow chart of publications in Castellsague et a
June 2014time diagnosis in a hospital of an UGIB during the
reference period. Across all case-control studies, 169 GI
events among patients using diclofenac were identiﬁed.
Because of the nature of a cohort study, sample sizes
in these studies are typically larger than for case-control
studies. Of the 2 cohort studies, Perez-Gutthann et al21
included 22,146 diclofenac users and Rahme et al18
included 778,759 diclofenac users, for a total of
800,905 exposed individuals. The study period for
the cohort studies ranged from 2 to 8 years. The
number of GI events among diclofenac users was not
reported for these 2 cohort studies.
Of the 7 studies, 3 deﬁned exposure as any
diclofenac use up to 7 days before the event date, 1
study deﬁned exposure as any diclofenac use up to 30
days before the event date, 1 study deﬁned exposure
as up to 90 days before the event date, and the
remaining 2 studies required that the prescription
period include the event date. Most studies required
information from endoscopy or other diagnostic tests
to conﬁrm UGIB.CV Studies
Of the 51 CV publications used in the McGettigan
and Henry8 meta-analysis, 27 articles included
diclofenac. Of these, 11 reported dosing informationNo usable dosing information
(n = 3)
Reason for exclusion
No dosing information
(n = 20)
Reason for exclusion
Diclofenac not present
(n = 29)
Reason for exclusion
l7 eligible for the gastrointestinal meta-regression.
909
Individual studies used in meta-analysis by
McGettigan and Henry8
(n = 51)
Studies with diclofenac information
(n = 27)
Studies eligible for meta-regression
(n = 11)
Reason for exclusion
Diclofenac not present
(n = 22)
Duplicate study
(n = 2)
Reason for exclusion
No usable dosing information
(n = 2)
Research letter
(n = 1)
Reason for exclusion
No dosing information
(n = 13)
Studies with any dosing information
(n = 14)
Figure 2. Flow chart of publications in McGettigan and Henry8 eligible for the cardiovascular meta-regression.
Clinical Therapeuticsfor oral diclofenac and were eligible for the meta-
regression analysis (Figure 2). Of the 11 CV studies, 6
were case-control studies and 5 were cohort studies.
For the case-control studies, the sample size for the
cases ranged from 3000 to 800,000, whereas the
sample size for controls ranged from 14,000 to
400,000. Cases typically were deﬁned as adult pa-
tients with a ﬁrst diagnosis of AMI, stroke, or other
CV event during the reference period. Across all case-Table I. Studies used in the gastrointestinal (GI) meta-r
Observation
No. Author, Year G
1 Castellsague et al, 200917 Upper GI
2
3 Gutthann et al, 199722 Complicat
4
5 Laporte et al, 200423 Upper GI
6
7
8 Perez-Gutthann et al, 199921 Upper GI
9 Rahme et al, 200718 Hospitaliz
GI bleed
10 Sakamoto et al, 200624 Upper GI
11 Savage et al, 199325 Complicat
910control studies, the total number of CV events for
cases using diclofenac was 2472. Sample sizes of the
eligible cohort studies ranged from 48,000 to 1
million patients. Some cohort studies identiﬁed the
subset of patients who used diclofenac; subsets ranged
from 804 patients to 172,362 patients, for a total of
189,211 exposed individuals. In the cohort studies,
the study period averaged 8 years, and patient medical
records from 1995 to 2005 were reviewed. Theegression model.
I Event
Diclofenac
Daily Dose (mg)
Risk Ratio
(95% CI)
hospitalization 75 2.30 (0.8–6.7)
100 2.00 (0.8–4.6)
ed ulcer 75 2.90 (1.4–5.7)
150 3.30 (1.6–7.0)
bleeding 50 1.80 (1.0–3.1)
100 4.20 (1.3–7.6)
150 18.20 (6.8–48.7)
bleeding 75 2.40 (0.5–4.6)
ation for upper
ing
150 3.78 (2.9–3.9)
bleeding 75 10.90 (2.5–48.4)
ed ulcer 150 3.30 (1.6–6.9)
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less frequently for cohort studies than for case-control
studies. For those studies that did provide event
information, the total number of CV events for
diclofenac users was 300. In general, diclofenac
exposure was deﬁned as any current diclofenac use up
to 30 days before the event date (ie, the day on which
the CV event occurred), although this varied from 7
days to 90 days before the event date.
Meta-Regression
GI Model
Table I17,18,21–25 provides a summary of the 11
doses and corresponding risk ratios from the 7 GI
studies. The results of the GI model indicated a positive
linear relationship between oral diclofenac dose and the
risk of a GI event; that is, as the diclofenac dose
increased, the risk of a GI event increased. The ﬁxed-
effect model parameter for diclofenac dose was
0.01776 (95% CI, 0.01361–0.02191), with an associ-
ated P value ofo0.001, indicating a linear relationship
between diclofenac dose and GI risk ratio. The follow-
ing equation converted diclofenac daily dosage (in
milligrams) to an estimated risk ratio that represented
risk per milligram of diclofenac dose: estimated GI risk
ratio ¼ (0.01776  daily dose) þ 1.Table II. Estimated risk of a serious gastrointestinal (G
dose of conventional and low-dose diclofenac.
Daily Dose
Conventional diclofenac
50 (eg, 25 mg BID)
100 (eg, 50 mg BID)
150 (eg, 50 mg TID)
Low-dose diclofenac*
36 (18 mg BID)
54 (18 mg TID)
70 (35 mg BID)
105 (35 mg TID)
*Trademark: Zorvolex® (Iroko Pharmaceuticals LLC, Philadelphia
conventional and low-dose diclofenac was takin into account w
70 mg, 54 mg and 36 mg of low-dose diclofenac were conver
diclofenac, respectively.
†The GI meta-regression model was based on a range of daily do
dose of diclofenac of 36 mg (adjusted to 38 mg) reﬂects an ap
the model37,38.
June 2014Table II provides the model-derived, estimated risk
ratios for a serious GI event for a range of daily diclo-
fenac doses (as found in conventional oral diclofenac and
low-dose oral diclofenac), compared with no exposure
(ie, NSAID nonuse). Figure 3 depicts the meta-regression
line, with the individual risk ratios plotted.
Additional models (eg, categorical dose, polyno-
mial transformations) and visual plots suggested that
the model with a linear effect for dose was appropriate
for describing the relationship between diclofenac
dose and the risk ratio of a GI event. We assessed
the model ﬁt and assumptions. We visually examined
model residuals for normality, and the plots showed
an approximate normal distribution of the residuals.
We examined outliers to see whether any observa-
tion contributed considerable inﬂuence on the regres-
sion line. We discovered a potential outlier in the
study reported by Sakamoto et al,24 a study conducted
in Japan with a small number of events (10 among
case subjects and 3 among control subjects), which
reported a risk ratio of 10.9. We performed a sen-
sitivity analysis by excluding this study, and the results
were compared with those from the main model (data
not shown). The sensitivity model results were similar
to those from the main model, indicating that the
effect of the study by Sakamoto et al was minimal, inI) event relative to nonuse of NSAIDs according to
*
Estimated GI Risk Ratio (SE; 95% CI)
1.89 (0.092; 1.68–2.10)
2.78 (0.184; 2.36–3.19)
3.66 (0.275; 3.04–4.29)
1.67 (0.070; 1.52–1.83)†
2.03 (0.106; 1.79–2.27)
2.33 (0.138; 2.02–2.64)
3.00 (0.207; 2.54–3.48)
, Pennsylvania). The difference in molecular weight between
hen dose was calculated. Speciﬁcally daily doses of 105 mg,
ted to 113 mc, 75 mg, 58 mg and 38 mg of conventional
ses as low as 50 mg; the GI risk ratio estimated for a daily
plication of the risk equation beyond the values included in
911
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Dose risk ratio data
Estimated GI risk ratio equation line
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5
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Figure 3. Relationship between diclofenac daily dose and the estimated risk ratio of a serious gastrointestinal
event. Numbers correspond to the observations in Table I.
Clinical Therapeuticspart because of its large variance and resulting low
weight. Our ﬁnal sensitivity analysis excluded the 2
studies that used a calculated incidence rate ratio in
the meta-regression analysis.18,21 The results were
comparable to those of the main model but with a
slightly lower ﬁxed-effect model parameter for diclo-
fenac dose (data not shown).
CV Model
Table III26–36 provides a summary of the 21 doses
and corresponding risk ratios from the 11 CV studies.
The results of the CV model indicated a positive linear
relationship for oral diclofenac dose and the risk
of a CV event. The ﬁxed-effect model parameter for
dose was 0.002585 (95% CI, 0.001655–0.003514)
with a P value o0.001, indicating a linear relation-
ship between diclofenac dose and CV risk ratio. The
following equation converted the diclofenac daily dose
in milligrams to an estimated risk ratio that repre-
sented risk per milligram of diclofenac dose: estimated
CV risk ratio = (0.002585  daily dose) þ 1.
Table IV provides the model-derived estimated risk
ratios for a CV event for a range of daily doses (as
found in conventional oral diclofenac and low-dose
diclofenac) compared with no exposure (ie, NSAID
nonuse). Figure 4 depicts the meta-regression line, with
the individual risk ratios plotted. The CV parameter
estimate was lower compared with the GI estimate,912therefore providing a lower model-derived estimated
risk ratio for a CV event. Similar to the GI model, we
assessed the linearity of the dose variable by examining
additional models (eg, categorical dose, polynomial
transformations) and visual plots. Linearity was not as
clear as in the GI model, particularly for 2 doses with
limited data (ie, 125 and 225 mg), for which the
relationship seemed to shift from the general linear
form. However, when reviewing all the evidence to-
gether, we deemed the linear dose model to be adequate
for describing the relationship between diclofenac dose
and the risk ratio of a CV event. Because the main
model analyzed a composite CV event end point, it was
of interest to construct a separate model that analyzed
only the studies that reported the risk ratio for AMI. Of
the 11 CV studies, 7 studies reported the risk ratio for
AMI. The results of this AMI model were comparable
to those of the main CV model, with a ﬁxed-dose
parameter of 0.002942 and a corresponding SE of
0.000438. We reviewed the model ﬁt and assumptions
for both the main CV and AMI models. We visually
examined model residuals for normality, and the plots
did not show any evident deviation from the normality
assumption. In addition, we examined the data for
outliers. We discovered a potential outlier in the study
reported by Gislason et al32: the dose of 125 mg was
associated with a risk ratio of 9.1. The authors did not
provide the sample size associated with the speciﬁcVolume 36 Number 6
Table III. Studies used in the cardiovascular meta-regression model.
Observation
No. Author, Year Cardiovascular Event
Diclofenac Daily
Dose (mg)
Risk Ratio
(95% CI)
1 Andersohn et al, 200626 Acute myocardial infarction 75 1.31 (1.06–1.62)
2 150 1.35 (1.13–1.61)
3 Bak et al, 200327 Stroke 100 1.10 (0.7–1.7)
4 Fischer et al, 200528 Acute myocardial infarction 75 1.22 (0.96–1.56)
5 100 1.25 (0.85–1.83)
6 Fosbøl et al, 201029 Coronary death or nonfatal
myocardial infarction
75 0.96 (0.59–1.57)
7 100 2.01 (1.56–2.59)
8 García Rodríguez et al, 200830 Acute myocardial infarction 75 1.51 (1.20–1.89)
9 150 1.80 (1.49–2.18)
10 Gislason et al, 200631 Acute myocardial infarction 75 1.66 (1.04–2.63)
11 100 1.69 (0.96–2.98)
12 Gislason et al, 200932 Acute myocardial infarction 75 1.18 (0.81–1.72)
13 125 9.10 (3.45–23.98)
14 Ray et al, 200933 Cardiovascular disease or death 100 1.43 (1.14–1.78)
15 150 1.34 (1.09–1.65)
16 Roumie et al, 200934 Composite cardiovascular event 125 1.01 (0.76–1.34)
17 van Staa et al, 200835 Acute myocardial infarction 100 1.30 (1.20–1.40)
18 150 1.50 (1.38–1.62)
19 225 1.35 (0.97–1.88)
20 300 2.28 (1.23–4.24)
21 Varas-Lorenzo et al, 200936 Acute myocardial infarction 100 1.02 (0.75–1.38)
D.M. Odom et al.result; however, because of the high associated variance,
we speculated that the result was based on a small
sample size. Because the study contributed 2
observations to the analysis and the lower dose result
was in line with the other results, it was not reasonable
to exclude the higher-dose observation but reasonable to
include the lower-dose observation. Therefore, we did
not exclude any data from this study.
We performed a ﬁnal sensitivity analysis that
excluded studies which assessed CV events associated
with rehospitalization. Three studies examined pa-
tients after their initial CV event to estimate the risk of
a repeat hospitalization for a CV event associated with
diclofenac use.31–33 The sensitivity analysis results
were comparable to those of the main CV model
results, suggesting that the studies which assessed CV
events associated with rehospitalization did not sig-
niﬁcantly inﬂuence the relationship between diclofe-
nac dose and risk of a CV event (data not shown).June 2014DISCUSSION
Summary of Results and Interpretation
We examined the relationship between oral diclofenac
dosage and toxicity of GI and CV events by using
observational studies identiﬁed in 2 previous systematic
reviews.7,8 Although previous meta-analysis studies have
reported that higher doses of NSAIDs are associated with
an increased risk of these events, the comparison was
made by using nonspeciﬁc categories of high and low
NSAID doses. We extended this research by modeling
dose as a continuous measure, allowing an assessment of
the risk of safety events for patients taking speciﬁc
diclofenac doses compared with NSAID nonusers.
Although the ﬁxed-effect model parameter for CV events
was smaller than the GI events, the results from both
models indicated positive linear relationships between
diclofenac dose and the risks for a GI or CV event. The
models may be used to explore the potential beneﬁts of
low-dose oral diclofenac. For example, substitution of913
Table IV. Estimated risk of a cardiovascular
event relative to nonuse of NSAIDs
according to dose of conventional
and low-dose diclofenac.*
Daily Dose
Estimated Risk Ratio
(SE; 95% CI)
Conventional diclofenac
50 (eg, 25 mg BID) 1.13 (0.022; 1.08–1.18)†
100 (eg, 50 mg BID) 1.26 (0.044; 1.17–1.35)
150 (eg, 50 mg TID) 1.39 (0.067; 1.25–1.53)
Low-dose diclofenac*
36 (18 mg BID) 1.10 (0.017; 1.06–1.13)†
54 (18 mg TID) 1.15 (0.026; 1.10–1.20)†
70 (35 mg BID) 1.19 (0.033; 1.12–1.26)
105 (35 mg TID) 1.29 (0.050; 1.19–1.40)
*Trademark: Zorvolex® (Iroko Pharmaceuticals LLC,
Philadelphia, Pennsylvania). The difference in molecular
weight between conventional and low-dose diclofenac
was takin into account when dose was calculated.
Speciﬁcally daily doses of 105 mg, 70 mg, 54 mg and
36 mg of low-dose diclofenac were converted to 113 mc,
75 mg, 58 mg and 38 mg of conventional diclofenac,
respectively.
†The cardiovascular meta-regression model was based
on a range of daily doses as low as 75 mg; the
cardiovascular risk ratios estimated for daily doses of
conventional oral diclofenac of 50 mg and of low-dose
diclofenac of 54 mg (adjusted to 58 mg) and 36 mg
(adjusted to 38 mg) reﬂect applications of the risk
equation beyond the values included in the model.
Clinical Therapeutics105 mg daily of low-dose oral diclofenac for the 150-mg
daily dose of conventional oral diclofenac was estimated
to reduce the risk of serious GI events by 18% and of
serious CV events by 7%. To our knowledge, this is the
ﬁrst meta-regression estimating the relationship between
daily dose as a continuous measure and risk of GI and
CV events, and it provides further support for guidelines
that explicitly recommend the use of NSAIDs at the
lowest effective dosage for the shortest duration.Advantages and Limitations
The use of observational studies in our meta-
regressions is a strength compared with designs that
included only randomized controlled trials (RCTs). In
general, RCTs are focused on primary efﬁcacy results and914have insufﬁcient power to detect group differences in rare
adverse events.39 Observational studies have the potential
to approximate more closely the real-world effect of the
intervention and can comprise a much larger number of
patients, including minority or vulnerable populations,
than would be practical for an RCT and are always
necessary to adequately assess harm.40 The Agency for
Healthcare Research and Quality also recommends
conducting comparative effectiveness analyses by using
data from observational trials.15 Our analyses included
data on 42500 diclofenac users experiencing CV events
and 4300 diclofenac users experiencing GI events.
Our analyses, which attempted to use every study
included in the 2 systematic reviews that provided
information on diclofenac dosage, modeled dose as a
continuous measure. This was accomplished by associat-
ing speciﬁc doses with risk effects based on the informa-
tion presented in each individual article from these
systematic reviews. Two rheumatologists who are expert
in the use of NSAIDs reviewed all dosages and conﬁrmed
the daily dose category used in the meta-regression.
Because our models examined all information provided
in each study, it was necessary to use sophisticated
modeling techniques to account for the fact that, if studies
reported 41 result (ie, risk ratios reported for multiple
dose categories), these results from the same study are
correlated. We modeled the adjusted estimates, when
available, of the risk ratios from each study (as is
appropriate for meta-analyses of observational studies).
There are several limitations to our work. Foremost,
we did not conduct an independent systematic review of
the literature and instead relied on 2 existing, recently
published systematic literature reviews that met the goals
of our study. Castellsague et al7 reviewed literature
published in English and included in the PubMed
database from 1980 through 2011. McGettigan and
Henry8 reviewed literature without language restrictions
from 1985 through 2010 in the following databases:
Medline, EMBASE, PubMed, Cochrane Library, Google
Scholar, epidemiologic research Web sites, abstracts of
scientiﬁc meetings, and bibliographies of relevant studies.
Although these were recent searches, there is a possibility
that newer literature has been published that could
inﬂuence results. To assess this limitation, we performed
a limited literature search by using PubMed to identify
any new literature published from 2010 through January
2012; no new articles were found that met our eligibility
criteria. The majority of the databases used in these
search criteria do not include information on unpublishedVolume 36 Number 6
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Figure 4. Relationship between diclofenac daily dose and the estimated risk ratio of a cardiovascular event.
Numbers correspond to the observations in Table III.
D.M. Odom et al.studies, nor did we conduct a separate review of
unpublished literature to minimize publication bias. We
also excluded other adverse events including renal
dysfunction, hypertension, exacerbation of congestive
heart failure, less serious upper GI events (eg, uncompli-
cated ulcer, dyspepsia), and lower GI events.
With any meta-analysis, heterogeneity across individ-
ual studies included in the meta-analysis is a potential
limitation. Although the populations across individual
studies generally were similar, some did examine distinct
patient populations (eg, patients rehospitalized after ﬁrst
AMI, patients aged Z50 years). For most studies,
diclofenac exposure and outcomes were based on avail-
able and typically limited information collected in large
databases. A variety of GI and CV outcomes were
presented, and we imposed a hierarchy of outcomes for
use in the analysis. We assumed that it was appropriate
to combine different outcomes in a single analysis (eg,
AMI and stroke) based on the fact that these outcomes
were similar in nature with similar risk proﬁles; this
method was conﬁrmed by our rheumatology experts and
was the method used by McGettigan and Henry8 in their
meta-analysis. Lastly, we assumed a linear relationship
between diclofenac dose and GI or CV events and
examined this linearity assumption by using the various
techniques described earlier. However, we were limitedJune 2014by the relatively small number of studies supplying
observations to the model.
CONCLUSIONS
Our analysis found a continuous linear dose relationship
between speciﬁc diclofenac doses and the risk of a serious
GI or CV event and provides further support for guide-
lines that recommend the use of NSAIDs at the lowest
effective dose for the shortest duration. Compared with
the risk of these events for comparable patients who are
not taking NSAIDs, the risk of serious GI and CV events
is expected to increase as diclofenac dosage increases.
Using this relationship, the risk of serious GI and CV
adverse event occurring at any daily dose of diclofenac
can be estimated. This is particularly helpful because a
new low-dose diclofenac drug product recently has
become available in the United States. Although our
ﬁndings are consistent with other published studies that
found high doses of NSAIDs to be associated with
increased risk of GI and CV events, more data are
needed to deﬁnitively quantify the relationship between
diclofenac and GI and CV events.
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